Drug Watch

Phase 2 trial of oveporexton for narcolepsy type 1 finds improvement on measures of cognition, in addition to previously demonstrated improved hallmark symptom of nighttime wakefulness.

Lipocine's oral brexanolone (LPCN 1154) for the treatment of postpartum depression failed to meet the primary endpoint in a phase 3 placebo-controlled trial.

New initiation of the Brilliance Studies, a phase 3 program evaluating the safety and efficacy of alixorexton compared to placebo in adults with narcolepsy type 1 and type 2.

Q1 psychiatric pipeline shifts: wins, setbacks, and standout trials in depression, schizophrenia, Alzheimer disease, and narcolepsy—what to watch next.

Check out the pipeline updates from March!

Further data shared on LB-102 for schizophrenia.

A panel of experts presented new consensus recommendations focused on the screening, diagnosis, and treatment of tardive dyskinesia among older adults in long-term care settings.

Tazbentetol interim results show improvement in schizophrenia symptoms.

LB Pharmaceuticals has initiated the pivotal phase 3 NOVA-2 trial evaluating the efficacy and safety of LB-102 as a treatment for schizophrenia.

AD/PD 2026 highlights oral blarcamesine preserving brain volume and IV lecanemab sustaining use while clearing amyloid-beta.

Intranasal BPL-003 shows rapid, sustained depression relief in treatment-resistant patients.

Phase 2 study tests AL001 brain-targeted lithium in bipolar I, aiming to cut toxicity and monitoring via advanced MRI/MRS imaging.

Guy Goodwin, MD, provides insights into COMP360 psilocybin and recent trial results, as well as psychedelics as a whole and their role in psychiatry.

New phase 2 data show HLP004 boosts standard antidepressants for moderate-to-severe GAD.

Phase 2 trial finds BXCL501 eases methadone-taper opioid withdrawal, outperforming lofexidine with simpler dosing and fewer adverse effects.

Check out the pipeline updates from February!

FDA clears Bysanti, a novel atypical antipsychotic for acute bipolar I and schizophrenia, leveraging Fanapt data; US launch planned 2026.

The FDA accepts Teva’s once-monthly olanzapine injection for schizophrenia, promising steadier adherence without mandatory 3-hour monitoring.

FDA feedback for CYC-126: anesthetic therapy with live EEG guidance aims to deliver precise relief for treatment-resistant depression.

IV DMT psychedelic SPL026 reduces major depression in phase 2a.

Phase 3 trial shows COMP360 psilocybin rapidly reduces treatment-resistant depression symptoms with durable effects and good safety, as Compass moves toward FDA review.

FDA reviews INmune Bio’s biomarker-enriched Phase 2b/3 plan for XPro1595.

Data and Safety Monitoring Board finds no safety issues for buntanetap at 6 months, keeping Annovis’ phase 3 early Alzheimer disease trial on track as enrollment progresses.

A new liquid stimulant option promises up to 14-hour ADHD symptom control and flexible dosing for adults and kids who struggle with capsule medication.

Denovo teams with Orygen to test DB103, a glutamate-targeting therapy, in a phase 2 youth trial for early psychosis.